Clinical-stage drug development company Invion Limited (ASX:IVX) is delighted to invite investors to listen to Managing Director and CEO, Dr Greg Collier, as he provides further background to yesterday’s announcement on Invion’s global licence agreement to develop an inhaled version of zafirlukast for the treatment of asthma and other respiratory conditions. In this audiocast, Dr Collier discusses:
- The important points of note for Invion investors, what zafirlukast will be used to treat and why Invion has in-licenced the drug at this time
- How this strategy fits in with Invion’s other clinical programs
- The likely clinical pathway for development of INV104 (zafirlukast) and milestones that investors can watch for
To access the audiocast, please visit this link:
FOR MORE INFORMATION CONTACT
Managing Director and CEO: Dr Greg Collier. P: 07 3295 0506 firstname.lastname@example.org
Media/ IR: Jane Lowe, Buchan Consulting P: 02 9237 2800 email@example.com
About INV104 (zafirlukast)
INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) or anti leukotriene that works by blocking the action of leukotrienes, which are chemicals released by the body as part of the inflammation response. In the lungs, leukotrienes cause the muscles lining the airways to contract, thereby making the airways narrower. They also cause inflammation of the lining of the airways, which results in increased mucus production and further narrowing of the airway. By blocking the actions of leukotrienes, zafirlukast prevents the increased mucus production, inflammation and narrowing of the airways that occurs in asthma – this helps prevent asthma attacks from occurring. Zafirlukast is currently used as a regular oral treatment to prevent asthma attacks, rather than to treat them. The oral version of this drug is a first-in-class anti-leukotriene, which has shown in seven clinical trials an attractive safety and efficacy profile when delivered by inhalation at <1% of the oral dose. Invion is developing an inhaled version of the drug.
About Invion Limited
Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) or anti-leukotriene that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein shown to reduce interlukin-6 (IL-6), a marker of autoimmune inflammation and a key marker in the chronic inflammatory disease, lupus. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA.